Maze Therapeutics GAAP EPS of -$0.77 misses by $0.09

2 hours ago 1

Maze Therapeutics press release (NASDAQ:MAZE): Q2 GAAP EPS of -$0.77 misses by $0.09.
Cash and cash equivalents were $264.5 million as of June 30, 2025, compared to $196.8 million as of December 31, 2024. Maze expects that its current cash and cash equivalents will fund operations into the second half of 2027.

Recommended For You